CN116035936A - 一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用 - Google Patents
一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116035936A CN116035936A CN202310230082.8A CN202310230082A CN116035936A CN 116035936 A CN116035936 A CN 116035936A CN 202310230082 A CN202310230082 A CN 202310230082A CN 116035936 A CN116035936 A CN 116035936A
- Authority
- CN
- China
- Prior art keywords
- percent
- composition
- skin
- extract
- hexanediol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 28
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 22
- 238000013271 transdermal drug delivery Methods 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- KOGFZZYPPGQZFZ-QVAPDBTGSA-N (2s,3r,4s,5r)-2-(2-hydroxypropyl)oxane-3,4,5-triol Chemical compound CC(O)C[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O KOGFZZYPPGQZFZ-QVAPDBTGSA-N 0.000 claims abstract description 14
- 241001071795 Gentiana Species 0.000 claims abstract description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 36
- 102000008186 Collagen Human genes 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 23
- 229920001436 collagen Polymers 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 21
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 16
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 16
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 15
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 14
- 239000003906 humectant Substances 0.000 claims description 14
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 8
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 8
- 108010014258 Elastin Proteins 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- 229960000458 allantoin Drugs 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- 229960003237 betaine Drugs 0.000 claims description 8
- 229920002549 elastin Polymers 0.000 claims description 8
- 229910003472 fullerene Inorganic materials 0.000 claims description 8
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 229920001285 xanthan gum Polymers 0.000 claims description 8
- 239000000230 xanthan gum Substances 0.000 claims description 8
- 229940082509 xanthan gum Drugs 0.000 claims description 8
- 235000010493 xanthan gum Nutrition 0.000 claims description 8
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 7
- 229920002498 Beta-glucan Polymers 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 230000002335 preservative effect Effects 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229940074410 trehalose Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- 241001369613 Stephania tetrandra Species 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 3
- 229960002216 methylparaben Drugs 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008236 heating water Substances 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004207 dermis Anatomy 0.000 abstract description 10
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 abstract description 8
- 230000014759 maintenance of location Effects 0.000 abstract description 7
- 239000003963 antioxidant agent Substances 0.000 abstract description 6
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 210000002615 epidermis Anatomy 0.000 abstract description 6
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 abstract description 5
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 abstract description 5
- 239000011148 porous material Substances 0.000 abstract description 3
- 229940021025 stephania tetrandra root extract Drugs 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 45
- 230000000052 comparative effect Effects 0.000 description 31
- 238000012360 testing method Methods 0.000 description 16
- 150000003254 radicals Chemical class 0.000 description 13
- 229960005150 glycerol Drugs 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 239000010410 layer Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 230000032683 aging Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940096422 collagen type i Drugs 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- -1 Glycerol glucoside Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- ATOTUUBRFJHZQG-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 ATOTUUBRFJHZQG-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000004994 Fagus sylvatica subsp sylvatica Nutrition 0.000 description 1
- 241000501719 Gentiana straminea Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960003357 pamabrom Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 150000003741 xylose derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用，涉及化妆品技术领域。本发明提供的组合物，在常规保湿成分的基础上，利用羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物的协同，具有较好的透皮作用，从而使得保湿成分、抗氧化成分能过透过表皮层到达真皮层，从而使得自由基降低，获得抗皱、保湿效果。此外，粉防己提取物与乙酰基六肽‑8的协同，能够使得毛孔收缩，从而持续锁水，实现长效保湿。
Description
技术领域
本发明涉及化妆品技术领域，特别是涉及一种具有透皮给药能力的抗皱、保湿组合物，且还涉及所述组合物的制备方法。此外，本发明还涉及所述组合物的应用，如用于化妆品制备中。
背景技术
随着年龄的增长，人体内成纤维细胞的数量逐渐减少，因此其分泌的胶原蛋白和弹力纤维蛋白也因为被氧化逐渐减少、断裂，真皮层开始变薄，皮肤弹性变差，皱纹也开始逐渐产生。当真皮层的胶原蛋白被氧化、断裂后，对表皮的支撑作用减少，因此造成不均一的塌陷，从而皱纹。人体内有一种酶叫SOD，SOD是清除人体内自由基垃圾的一种物质。随着年龄的增长，SOD活性逐渐减弱，体内垃圾难以清除，这些自由基产生的垃圾是一种有毒的物质，是造成人体老化的有害物质。采用含有去除自由基和抗氧化的化妆品进行护理，可一定程度上延缓皮肤皱纹的发生，使皮肤保持弹性和细腻；但是由于环境因素导致的肌肤损伤，使皮肤对有效的成分的吸收作用降低，抗皱作用低。
“缺水”是肌肤越变越糟及老化的最主要元凶之一，补水保湿不只是敏感肌肤的专利，各种皮肤都会因为环境、年龄、营养、健康等因素而缺水，当人体皮肤的角质层水分含量低于10％时，皮肤就会失去细柔、弹性、继而变得粗糙、干燥、出现各种皮肤异常，若长期得不到纠正，皮肤容易老化、长斑变得敏感，所以抗衰的同时也要注意补水。
但是，现有的抗皱、保湿化妆品都存在吸收率(透皮率)低，效果不明显的问题。
综上，迫切需要开发一种兼顾抗皱、保湿且吸收效果明显的化妆品组合物。
发明内容
鉴于上述问题，本发明对现有抗皱、保湿化妆品组合物的成分和性能进行研究，经过不断试验和创新，获得一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用，该组合物具有透皮给药能力，从而使得皮肤保湿效果明显，具有抗皱功效。该组合物中的羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物协同，使得其具有良好的透皮给药能力；同时配方组分的结合，使得抗皱、保湿效果明显。
为了实现上述目的，在本发明的第一方面，提供了一种具有透皮给药能力的抗皱、保湿组合物，按重量百分比计，其原料组分包括以下组分：
保湿剂6-8％、丙二醇3-5％、丁二醇0.8-1％、弹性蛋白0.001-0.003％、对羟基苯乙酮0.4-0.6％、富勒烯0.0002-0.0003％、甘油6-10％、甘油葡糖苷0.15-0.3％、黄原胶0.0005-0.0008％、精氨酸0.02-0.04％、精氨酸/赖氨酸多肽0.001-0.003％、可溶性胶原0.001-0.003％、氯化钠0.008-0.012％、羟丙基四氢吡喃三醇1-3％、乙酰基六肽-80.1-0.2％、防腐剂0.03-0.05％、龙胆提取物0.01-0.02％、粉防己提取物0.001-0.002％、水余量。
优选地，所述组合物的原料组分包括以下组分：
保湿剂7-8％、丙二醇3-4％、丁二醇0.8-0.9％、弹性蛋白0.001-0.002％、对羟基苯乙酮0.4-0.5％、富勒烯0.0002-0.0003％、甘油6-8％、甘油葡糖苷0.15-0.2％、黄原胶0.0005-0.0007％、精氨酸0.02-0.03％、精氨酸/赖氨酸多肽0.001-0.002％、可溶性胶原0.001-0.002％、氯化钠0.009-0.01％、羟丙基四氢吡喃三醇1-2％、乙酰基六肽-80.1-0.18％、防腐剂0.03-0.05％、龙胆提取物0.01-0.02％、粉防己提取物0.001-0.002％、水余量。
优选地，所述保湿剂包括1,2-己二醇、尿囊素、1,2-戊二醇、海藻糖、甜菜碱、透明质酸钠、透明质酸、燕麦β-葡聚糖、甘油聚醚-26中的至少两种。值得注意的是，保湿剂中的透明质酸钠与其他常用的保湿剂一样，用于提高组合物的保湿剂作用，改善皮肤干燥状态，提高皮肤的含水量。其中，1,2-己二醇、1,2-戊二醇还可作为溶剂使用。
更为优选地，所述保湿剂为1,2-己二醇、尿囊素、1,2-戊二醇、海藻糖、甜菜碱、透明质酸钠、燕麦β-葡聚糖、甘油聚醚-26的组合。
更为优选地，按重量百分比计，所述保湿剂占原料组分的含量分别为：
1,2-己二醇0.5-0.6％、尿囊素0.1-0.3％、1,2-戊二醇0.2-0.4％、海藻糖0.15-0.25％、甜菜碱2-3％、透明质酸钠0.4-0.6％、燕麦β-葡聚糖0.05-0.07％、甘油聚醚-261.5-3％。
优选地，所述防腐剂包括甲酯、苯氧乙醇、乙基己基甘油、羟苯甲酯、羟苯乙酯中的任意一种。
丙二醇，在护肤品中主要作为保湿剂、溶剂、增溶剂使用。
弹性蛋白，能促进皮肤充分的吸收，增加肌肤胶原蛋白和弹性蛋白含量，显著提高肌肤内部张力和弹力，使皮肤的胶原蛋白活性加强，保持角质水分，由内而外的改善并减少皱纹，提高紧致感，增加皮肤弹性从而延缓衰老的功效。
丁二醇，在化妆品中常被用做溶剂和保湿剂来使用，同时也有一定的抑菌作用。
对羟基苯乙酮，在化妆品里面主要是作为防腐剂使用，同时具有抗氧化、镇静舒缓的功能。在本发明中，主要作为抗氧化剂使用。
粉防己提取物，具有广谱抗炎作用，对炎症反应的各个环节均有不同程度的抑制作用；粉防己提取物对毛孔有很好的收敛作用，可用于紧肤肌肤。
富勒烯，具有超强的消除人体自由基能力，抗氧化效果强且稳定，已被录入在SFDA目录中，富勒烯的抗氧化能力是VC的172倍，是SOD的50多倍，被誉为抗氧化之王；2014年6月30日，富勒烯正式被国家食品药品监督管理总局收录进《已使用化妆品原料名称目录》。
甘油，在化妆品、护肤品里主要作用是溶剂、保湿剂。
甘油葡糖苷(αGG)，是一种糖苷化合物，由葡萄糖基和甘油组成，是微生物在胁迫条件下合成的一种渗透保护物质；它可以保护细胞免受渗透压、热、干旱和紫外线等恶劣环境的破坏。其分子量比透明质酸钠小5000多倍，具有保湿、抗氧化、抗衰老以及细胞修复等功效，可以消除洁面后皮肤的紧绷感。本发明利用多种保湿成分从源头开始，直达真皮层，促使αGG加快老化细胞中I性胶原蛋白前体的合成，增加肌肤的弹性和光滑度，增加细胞活力和新陈代谢，激活再生皮肤细胞。在低水合状态下，膜之间的水很少，膜面受到侧向应力，变成胶状，胶化后的膜，单个脂分子面积降低，膜厚度增加，而αGG的渗透和体积能使水合作用提高，膜间距增大，侧向应力降低，膜在低水合状态下依然能保持流体状，提高细胞膜的稳定性，锁住水分。
黄原胶，分子中含有大量的亲水基团，是一种良好的表面活性物质，并具有抗氧化、防止皮肤衰老等功效，因此，几乎绝大多数高档化妆品中都将黄原胶作为其主要功能成分。此外，黄原胶还可作为牙膏的成分实质增稠定型，降低牙齿表面磨损。
精氨酸，是鸟氨酸循环中的一个组成成分，具有极其重要的生理功能。多吃精氨酸，可以增加肝脏中精氨酸酶的活性，有助于将血液中的氨转变为尿素而排泄出去。
精氨酸/赖氨酸多肽，一种由多种氨基酸组成的混合物，作为调理剂，有助于刺激细胞外基质结构成分的合成和累积，还有帮助抑制无序胶原蛋白交联和金属蛋白酶的释放；促进纤维母细胞再生，刺激合成胶原蛋白，恢复皮肤弹性。具有较好的防老、抗皱效果。
可溶性胶原，其广泛分布于人体组织，是组成人体重要的蛋白质，占人体总蛋白含量30％以上；依据氨基酸序列不同分为28种型号，其中Ⅰ型胶原蛋白含量占胶原蛋白总量的80％左右，Ⅰ型、Ⅱ型、Ⅲ型胶原蛋白之和占胶原蛋白总量90％以上。可溶性胶原主要作用是维持皮肤和组织器官的形态和结构，同时也是修复各损伤组织的重要原料物质。本申请优选采用类皮胶原(INCI名：可溶性胶原)，其属于Ⅰ型胶原蛋白，与人体皮肤结构相似，分子量较小，易于透过皮肤表皮而被真正吸收；其能够通过促进细胞活性和极性而达到抗衰的功效，还可修复皮肤角质层，对人体角质细胞有一定的促进修复作用，促进皮肤屏障提升，修复皮肤红斑，促进透明质酸再生。本申请对于可溶性胶原的来源不做特别的限定，只要能够实现本申请的发明目的即可，例如，采用珠海柏瑞医药公司制备的可溶性胶原(BeriCosTMCollagen类皮胶原蛋白)作为护肤品组合物中的组分。
龙胆提取物，是从龙胆科植物条叶龙胆、坚龙胆的根及茎中提取的物质，具有清热燥湿的功效，可改善皮肤干、痒等敏感不适的状态，增强皮肤天然免疫力，也可使皮肤增白和保湿。
氯化钠，用于化妆品中增加粘合强度。
羟丙基四氢吡喃三醇，是一种源于西欧山毛榉木中的木糖类衍生物，最早由兰蔻实验室研发的一种抗衰老活性成分，具有促进胶原蛋白和糖胺聚糖合成功效，针对表皮与真皮连接处DEJ，帮助真皮维持弹性。
乙酰基六肽-8，可使囊包不能有效释放神经传导素，从而减少面部表情收缩，达到减轻皱纹的作用。
本发明中，羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物的协同，具有较好的透皮作用，从而使得保湿成分、抗氧化成分能过透过表皮层到达真皮层，从而使得自由基降低，获得抗皱、保湿效果。此外，粉防己提取物与乙酰基六肽-8的协同，能够使得毛孔收缩，从而持续锁水，实现长效保湿。
在本发明的第二方面，还提供了一种上述组合物的制备方法，包括如下步骤：
将水加热至100℃，保温10-30min冷却至85℃，加入尿囊素和甜菜碱，完全溶解的混合物Ⅰ；对羟基苯乙酮用丙二醇和1,2-己二醇在60℃完全溶解得混合物Ⅱ；将其余原料按照溶解性分别用水、丙二醇、1,2-己二醇、1,2-戊二醇、甘油中的一种或两种或多种的组合溶解，在45℃以下，与混合物Ⅰ和混合物Ⅱ混合，均质，即得。
需要说明的是，本领域技术人员可根据原料的溶解性，选择水、丙二醇、1,2-己二醇、1,2-戊二醇、甘油或者其中两种或多种的组合对原料进行溶解。还可以理解为，只要能将上述的原料组分用相应溶剂溶解，并能形成均质、无沉淀、无团聚的溶液即可。例如：
精氨酸/赖氨酸多肽、乙基己基甘油用1,2-己二醇和水溶解；
甘油葡糖苷、甜菜碱、乙酰基六肽-8用水、甘油、1,2-戊二醇、丙二醇溶解；
燕麦β-葡聚糖、羟苯甲酯用水、1,2-己二醇溶解；
海藻糖、精氨酸、氯化钠、弹性蛋白用水、1,2-己二醇和1,2-戊二醇溶解；
可溶性胶原、海藻糖、精氨酸、氯化钠用水、1,2-己二醇和1,2-戊二醇溶解；
黄原胶、富勒烯用丁二醇和水溶解；
粉防己提取物、龙胆提取物用水和丙二醇溶解；
剩余原料则可直接与混合物Ⅰ和混合物Ⅱ混合。
在本发明的第三方面，还提供了一种上述组合物的应用，所述应用为与其他赋形剂制成不同形态的化妆品。所述赋形剂可理解为化妆品可接受的赋形剂，例如表面活性剂或胶凝剂等。
与现有技术相比，本发明具有以下有益效果：
1.本发明通过多种保湿剂和抗氧化剂的复配，去除自由基能力强，使得组合物具有良好的保湿效果和抗皱效果。
2.本发明通过羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物的协同作用，使得其具有良好的透皮给药能力，吸收效果好。
3.本发明通过羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物的协同作用，使得皮肤具有良好的锁水性能，提升了持续保湿作用。
4.本发明的制备方法简单，考虑不同原料组分的溶解性，分别采用不同的溶剂进行复配，从而使得产品均匀，抗皱、保湿性能佳。
具体实施方式
为使本发明技术方案和优点更加清晰明了，下面结合具体实施例对本发明的技术方案进行更清楚完整的说明。在所述实施例中，所用设备如无做特殊说明的，即同常规聚氨酯所用生产设备相同。
在以下实施例中所用原料均为市售。
实施例1-4和对比例1-4
实施例1-4和对比例1-4的原料组分含量如表1所示。
表1实施例1-4和对比例1-4的原料组分含量
上述组合物按照如下方法进行制备：
1.把1号原料加入均质乳化锅中搅拌加热至100℃，保温20分钟，然后降温至85℃，然后加入10、17号原料，搅拌，使其完全溶解，然后取一清洁消毒过的容器，加入4、16号原料，搅拌，使其分散均匀，然后加入乳化锅，搅拌，均质，使其完全溶解，然后开冷却水，冷却至45℃；；
2.取一个干净消毒过的容器，加入5、13、14号原料搅拌加热至60℃，使其完全溶解
3.在45℃以下，加入(2)混合物，再加入2、3、6、7、8、9、11、12、15号原料搅拌均匀。
4.取样送化验室检验，合格出料。
5.放料至贮料桶内,放置静置间静置12小时。
6.静置12小时，静置好的料体经生产前化验，合格后送无菌灌装线准备灌装。生产整个过程确保顺畅、卫生和无菌。避免因操作不当引发细菌滋生和产品质变。
7.包装材料检验，消毒做无菌处理，经检验合格后进入生产线。
性能测试
透皮性能测试
试剂与材料
巴马香猪皮、乙腈(CINC，色谱级)、超纯水。
仪器
透皮扩散试验仪、LC-20AT液相色谱仪。
待测样品
实施例1-4和对比例1-4。
实验方法
巴马香猪背/腹部皮肤适当裁剪后固定于接收室和供给室之间，取待测样品各1mL于供给室中，以0.01M PBS缓冲液为接收液，接收液体积为15mL，37℃下300r/min搅拌。于24h取1mL接收液进行HPLC分析，分析条件：A流动相为0.1％TFA的纯水，B流动相为0.1％TFA的乙腈，柱温35℃，流速1mL/min。计算24h后的透过真皮百分比。
取下皮肤，用超纯水洗去样品残液后剪碎，转入组织匀浆器中充分研磨成匀浆液，加4mL PBS提取，微孔滤膜过滤后进行HPLC分析，计算皮内滞留百分比，结果如表2所示。
表2透皮性能测试
| 样品 | 透过真皮百分比％ | 皮内滞留百分比％ |
| 实施例1 | 0 | 28.63 |
| 实施例2 | 0 | 28.34 |
| 实施例3 | 0 | 28.45 |
| 实施例4 | 0 | 27.69 |
| 对比例1 | 0 | 12.34 |
| 对比例2 | 0 | 8.23 |
| 对比例3 | 0 | 11.26 |
| 对比例4 | 0 | 8.31 |
如表2所示，实施例的透皮给药能力较好。比较对比例1-3和实施例1，可明显看出羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物三者产生了协同作用，从而获得了较好的透皮给药能力。而对比例2和4可以看出，乙酰基六肽-8与粉防己提取物形成协同作用，皮内滞留比相较实施例和其余对比例更低，即锁水功效降低。
保湿效果测试：采用水分测试仪Corneometer(CM825，C+K公司，德国)测试水分含量。其度量所用单位A.C.U.；采用皮肤水份流失(TEWL)测试仪Tewameter(TM300，C+K公司，德国)测试水分流失率，皮肤保护层越完好，水份的含量就会越高，皮肤水份流失TEWL的数值就越低。测定环境：测试环境温度：22±3℃，湿度：50±5％。共选取45名试用者(年龄20-40岁)，分为9组(平均年龄28±2岁)，分别采用实施例1-4、对比例1-4所制备的组合物。每天均匀涂敷两次，使用前测试初始值，一个月后测试结果，观察变化率，结果表3所示。
表3保湿性能测试结果
需要说明的是，连续使用30d后皮肤平均水分含量是指连续使用30天后，不使用产品，直接测试的结果。由表3可知，实施例所制备的组合物的持续保湿性能佳，连续使用后，对皮肤的含水量有较为明显的改善。而从对比例1-3和实施例的变化率进行比较，结合表2可以看出，组合物的透皮给药能力明显影响到了保湿性能，即羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物三者产生了协同作用；而从对比例2、对比例4和实施例的变化率进行比较，结合表2可以看出，乙酰基六肽-8与粉防己提取物也形成了协同作用，共同提升了组合物的锁水性能。
抗衰抗皱测试
共选取45名志愿者(年龄段为40-60岁)，分为9组(平均年龄为50±2)，分别使用实施例1～4和对比例1～4，测试部位为两侧脸颊和眼角，每天使用2次，洁面后使用；在使用化妆品前1天，使用后30d，使用MicroSkinII多功能皮肤镜图像分析系统测定皮肤平均粗糙度和皱纹平均深度数值变化，计算平均值，见表4。通过表4变化率可见，使用本发明实施例1～4相对于对比例1～4，抗皱效果突出，皮肤粗糙和皮肤皱纹深度值显著改善。
表4抗皱性能测试结果
如表4所示，实施例的透皮给药能力较好。比较对比例1-3和实施例1，可明显看出羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物三者产生了协同作用，从而获得了较好的透皮给药能力。而对比例2和4可以看出，乙酰基六肽-8与粉防己提取物形成协同作用，皮内滞留比相较实施例和其余对比例更低，即锁水功效降低。
抗氧化能力测试
1.测试原理
自由基过量产生是导致皮肤自然衰老和光老化的主要原因。因此清除自由基能延缓皮肤衰老，减少皱纹。1,1-二苯基-2-三硝基苯肼(简称DPPH)是一种稳定的长寿命自由基，当有自由基清除剂存在时，由于与其单电子配对而使DPPH乙醇溶液光吸收减弱。DPPH乙醇溶液褪色程度与其接受的电子数呈线性关系，由此可评价试验样品清除自由基的能力，即抗氧化活性的大小。
2.受试物：
测试样品原物(实施例1-4和对比例1-4)：测试浓度为200mg/mL
3.测试方法：
对试验样品进行预处理，制成溶液。加入自由基DPPH，制备多管样品，摇匀，室温下静置一段时间后，上机测试测定517nm吸光值，计算样品清除自由基的能力并计算统计学差异P值，结果如表5所示。
表5自由基清除率结果
| 样品 | 自由基清除率，％ | P值 |
| 实施例1 | 62.65 | ＜0.05 |
| 实施例2 | 61.95 | ＜0.05 |
| 实施例3 | 62.45 | ＜0.05 |
| 实施例4 | 61.56 | ＜0.05 |
| 对比例1 | 30.25 | ＜0.05 |
| 对比例2 | 28.94 | ＜0.05 |
| 对比例3 | 29.34 | ＜0.05 |
| 对比例4 | 28.53 | ＜0.05 |
| 空白对照 | 0 | ＜0.05 |
P＜0.05表示具有统计学意义，由表5可知，实施例中提供的组合物具有良好的自由基清除效果；而比较实施例和对比例1-3的数据，可明显看出羟丙基四氢吡喃三醇、龙胆提取物和粉防己提取物三者产生了协同作用，从而获得了较好的透皮给药能力，使得抗氧化剂等能去除自由基的成分透过表皮层到达真皮层，从而获得较好的自由基清除效果。而对比例2和对比例4可以看出，乙酰基六肽-8与粉防己提取物形成协同作用，对比例4组合物具有透皮给药能力，但流失率较高，导致自由基清除效果不佳。
根据上述说明书的揭示和教导，本发明所属领域的技术人员还可以对上述实施方式进行变更和修改。因此，本发明并不局限于上面揭示和描述的具体实施方式，对发明的一些修改和变更也应当落入本发明的权利要求的保护范围内。此外，尽管本说明书中使用了一些特定的术语，但这些术语只是为了方便说明，并不对本发明构成任何限制。
Claims (8)
1.一种具有透皮给药能力的抗皱、保湿组合物，其特征在于，按重量百分比计，其原料组分包括以下组分：
保湿剂6-8％、丙二醇3-5％、丁二醇0.8-1％、弹性蛋白0.001-0.003％、对羟基苯乙酮0.4-0.6％、富勒烯0.0002-0.0003％、甘油6-10％、甘油葡糖苷0.15-0.3％、黄原胶0.0005-0.0008％、精氨酸0.02-0.04％、精氨酸/赖氨酸多肽0.001-0.003％、可溶性胶原0.001-0.003％、氯化钠0.008-0.012％、羟丙基四氢吡喃三醇1-3％、乙酰基六肽-80.1-0.2％、防腐剂0.03-0.05％、龙胆提取物0.01-0.02％、粉防己提取物0.001-0.002％、水余量。
2.根据权利要求1所述的组合物，其特征在于，按重量百分比计，所述组合物的原料组分包括以下组分：
保湿剂7-8％、丙二醇3-4％、丁二醇0.8-0.9％、弹性蛋白0.001-0.002％、对羟基苯乙酮0.4-0.5％、富勒烯0.0002-0.0003％、甘油6-8％、甘油葡糖苷0.15-0.2％、黄原胶0.0005-0.0007％、精氨酸0.02-0.03％、精氨酸/赖氨酸多肽0.001-0.002％、可溶性胶原0.001-0.002％、氯化钠0.009-0.01％、羟丙基四氢吡喃三醇1-2％、乙酰基六肽-80.1-0.18％、防腐剂0.03-0.05％、龙胆提取物0.01-0.02％、粉防己提取物0.001-0.002％、水余量。
3.根据权利要求1或2所述的组合物，其特征在于，所述保湿剂包括1,2-己二醇、尿囊素、1,2-戊二醇、海藻糖、甜菜碱、透明质酸钠、透明质酸、燕麦β-葡聚糖、甘油聚醚-26中的至少两种。
4.根据权利要求3所述的组合物，其特征在于，所述保湿剂为1,2-己二醇、尿囊素、1,2-戊二醇、海藻糖、甜菜碱、透明质酸钠、燕麦β-葡聚糖、甘油聚醚-26的组合。
5.根据权利要求4所述的组合物，其特征在于，按重量百分比计，所述保湿剂占原料组分的含量分别为：
1,2-己二醇0.5-0.6％、尿囊素0.1-0.3％、1,2-戊二醇0.2-0.4％、海藻糖0.15-0.25％、甜菜碱2-3％、透明质酸钠0.4-0.6％、燕麦β-葡聚糖0.05-0.07％、甘油聚醚-261.5-3％。
6.根据权利要求1所述的组合物，其特征在于，所述防腐剂包括甲酯、苯氧乙醇、乙基己基甘油、羟苯甲酯、羟苯乙酯中的任意一种。
7.权利要求1-6任一项所述的具有透皮给药能力的抗皱、保湿组合物的制备方法,其特征在于，包括以下步骤：
将水加热至100℃，保温10-30min冷却至85℃，加入尿囊素和甜菜碱，完全溶解的混合物Ⅰ；对羟基苯乙酮用丙二醇和1,2-己二醇在60℃完全溶解得混合物Ⅱ；将其余原料按照溶解性分别用水、丙二醇、1,2-己二醇、1,2-戊二醇、甘油中的一种或两种或多种的组合溶解，在45℃以下，与混合物Ⅰ和混合物Ⅱ混合，均质，即得。
8.权利要求1-6任一项所述的具有透皮给药能力的抗皱、保湿组合物在化妆品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310230082.8A CN116035936A (zh) | 2023-03-10 | 2023-03-10 | 一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310230082.8A CN116035936A (zh) | 2023-03-10 | 2023-03-10 | 一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116035936A true CN116035936A (zh) | 2023-05-02 |
Family
ID=86127575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310230082.8A Pending CN116035936A (zh) | 2023-03-10 | 2023-03-10 | 一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116035936A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344181A (zh) * | 2022-01-21 | 2022-04-15 | 苏州纯美印象生物科技有限公司 | 一种舒缓抗皱精华水及其制备方法 |
-
2023
- 2023-03-10 CN CN202310230082.8A patent/CN116035936A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344181A (zh) * | 2022-01-21 | 2022-04-15 | 苏州纯美印象生物科技有限公司 | 一种舒缓抗皱精华水及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 珠海市华中源生物科技有限公司: "OVLIENY青春逆龄抗皱精华素", pages 2, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=1080814568311095296&gb=G> * |
| 珠海市华中源生物科技有限公司: "奥姿活泉蛋白精华液", pages 2, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=1052254830988361728&gb=G> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7195324B2 (ja) | 肌修復用スキンケア組成物及びその調製方法 | |
| JP4904811B2 (ja) | α，α−トレハロースの糖質誘導体を含有することを特徴とする皮膚外用剤 | |
| JP7200211B2 (ja) | 皮膚、毛髪、爪および／または粘膜の処置および／またはケアに有用な化合物 | |
| CN116172891B (zh) | 一种多效保湿组合物及其制备方法 | |
| US8460721B2 (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
| EP2164858B1 (en) | Kghk peptide, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | |
| JP2008105985A (ja) | ヒアルロン酸産生促進剤、皮膚外用剤、浴用剤及び飲食物 | |
| CN109330954B (zh) | 美白亮肤水及其制备方法和酪氨酸酶抑制剂 | |
| CN113599338A (zh) | 一种含nmn抗衰老精华液及其制备方法 | |
| CN114588061A (zh) | 一种抗衰除皱组合物及其制备方法和护肤品 | |
| US10279076B2 (en) | Composition for maintaining efficacy of filler | |
| CN115721582A (zh) | 一种含有外泌体的抗衰老精华液及其制备方法 | |
| JP3435181B2 (ja) | メラニン生成抑制外用剤 | |
| JP3172753B2 (ja) | 生体ヒアルロン酸合成促進剤 | |
| CN112656731A (zh) | 一种具有修红功效的组合物及其制备方法和应用 | |
| JP2010006844A (ja) | インスリン様成長因子−１分泌促進剤 | |
| CN116889528A (zh) | 一种水光面膜及其制备方法 | |
| CN115024997B (zh) | 具有抗皮肤衰老功效的化妆品组合物 | |
| JP5610681B2 (ja) | 中性脂肪蓄積抑制剤 | |
| KR102382002B1 (ko) | 펩타이드 복합체 및 천연 성분을 함유하는 주름 및 피부탄력 개선, 타이로시네이즈 억제 등 다기능성 화장료 조성물 | |
| CN116035936A (zh) | 一种具有透皮给药能力的抗皱、保湿组合物及其制备方法和应用 | |
| CN115554186A (zh) | 一种多肽抗衰精华液及其制备方法 | |
| KR102281606B1 (ko) | 펩타이드 복합체를 함유하는 주름 및 피부탄력 개선, 타이로시네이즈 억제 등 다기능성 화장료 조성물 | |
| CN116158987A (zh) | 一种具有透皮给药能力的抗皱润肤组合物及其制备方法 | |
| CN108852977B (zh) | 一种晶润精华液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230502 |
|
| RJ01 | Rejection of invention patent application after publication |